Clinical Trials Directory

Trials / Sponsors / Pluristem Ltd.

Pluristem Ltd.

Industry · 11 registered clinical trials.

StatusTrialPhaseStarted
UnknownOpen-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Trea
Ionizing Radiation Exposure
Phase 12021-01-01
TerminatedOpen-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
COVID, ARDS
Phase 22020-10-19
TerminatedDouble-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19
COVID, ARDS
Phase 22020-10-01
CompletedTreatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)
Hip Fracture
Phase 32018-07-26
CompletedEfficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Cr
Critical Limb Ischemia (CLI)
Phase 32017-05-22
CompletedSafety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Fo
Incomplete HCT (Hematopoietic Cell Transplantation)
Phase 12017-02-08
CompletedSafety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)
Intermittent Claudication, Peripheral Artery Disease
Phase 22012-11-05
CompletedSafety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Tota
Total Hip Arthroplasty, Muscle Injury
Phase 1 / Phase 22012-11-01
CompletedSafety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemi
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Phase 12009-08-01
CompletedSafety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Phase 12009-06-01
No Longer AvailableExpanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuita
Critical Limb Ischemia (CLI)
——